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DOI 10.1016/j.ccr.2010.10.028SUMMARYTargeting mitotic exit has been recently proposed as a relevant therapeutic approach against cancer. By
using genetically engineered mice, we show that the APC/C cofactor Cdc20 is essential for anaphase onset
in vivo in embryonic or adult cells, including progenitor/stem cells. Ablation of Cdc20 results in efficient
regression of aggressive tumors, whereas current mitotic drugs display limited effects. Yet, Cdc20 null cells
can exit frommitosis upon inactivation of Cdk1 and the kinaseMastl (Greatwall). This mitotic exit depends on
the activity of PP2A phosphatase complexes containing B55a or B55d regulatory subunits. These data illus-
trate the relevance of critical players of mitotic exit in mammals and their implications in the balance between
cell death and mitotic exit in tumor cells.INTRODUCTION
Multiple efforts in the last two decades have been put toward the
evaluation of therapeutic advantages of cell cycle inhibition in
tumor cells (Malumbres and Barbacid, 2009). These strategies
include impairing the entry into the cell cycle by inhibition of
cyclin-dependent kinases (Cdks), arresting cells at the G1/S or
G2/M transitions with DNA-damaging agents, or inhibiting
mitotic progression by targeting microtubules or mitotic kinases
(Jackson and Bartek, 2009; Jordan and Wilson, 2004; Malum-
bres and Barbacid, 2001, 2007). In most cases, tumor prolifera-
tion is only transiently or partially reduced. For instance,
inhibiting G1 Cdks only results in minor defects given the
compensation between multiple family members, and G0/G1-
arrested cells can resume cell cycle proliferation upon activation
of the appropriate stimuli (Malumbres and Barbacid, 2009).
Checkpoint-mediated arrest can be transient once the insulting
conditions have been eliminated or repaired or as a result of
adaptation to the checkpoints (Syljuasen, 2007; Weaver and
Cleveland, 2005). In addition, resistance to microtubule poisonsSignificance
Despite the multiple efforts to inhibit the cell cycle in tumors, m
effects or by adaptation to the therapeutic conditions. We sho
anaphase onset in vivo. Genetic ablation of Cdc20 results in dra
parallel treatmentswith currentmitotic drugs displaymore limit
a PP2A-B55-dependent mitotic exit and protection from apo
pathway is likely to be critical for improving strategies aimed
Cancan be acquired by expression of particular tubulin isoforms or
microtubule-regulating proteins (Kavallaris, 2010), and cells
can display many variable fates following exposure to microtu-
bule drugs (Gascoigne and Taylor, 2008).
More recently, mitotic exit has been proposed as a relevant
target given the proapoptotic effect of RNA interference (RNAi)
against the anaphase-promoting complex/cyclosome (APC/C)
cofactor Cdc20 (Huang et al., 2009). Chromosome segregation
requires the activity of the APC/C, an E3 ubiquitin ligase that
targets critical cell cycle regulators for degradation (Peters,
2006; Sullivan and Morgan, 2007). APC/C recognizes its
substrates through two adaptor proteins, Cdc20 and Cdh1.
Cdc20 is responsible for APC/C function during the early phases
of mitosis and for triggering mitotic exit at the metaphase-to-
anaphase transition. Cdh1 activates the APC/C during the final
phases of mitosis and G1 (Peters, 2006). The current model
states that, upon complete bipolar attachment of all chromo-
somes to spindle microtubules, the activation of APC/C by
Cdc20 results in the elimination of two critical targets: securin,
a separase inhibitor; and cyclin B, the activating subunit ofost therapeutic approaches are limited due to compensatory
w in this manuscript that mammalian cells require Cdc20 for
matic tumor regression due to apoptotic cell death, whereas
ed effects. Inhibition of the kinases Cdk1 andMastl mediates
ptosis in Cdc20-depleted cells. Full understanding of this
to target mitotic exit for cancer treatment.
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Figure 1. Cdc20 Is Essential for Anaphase
Onset in Embryonic Cells
(A) Cdc20 null embryos (Figure S1) arrest at the
two-cell stage, whereas wild-type embryos prog-
ress to blastocysts by embryonic (E) days 3.5–
4.5. Scale bars, 20 mM.
(B) Immunofluorescence analysis of E3.5 embryos
showing normal mitotic figures in Cdc20(+/+)
morulas. Cdc20(/) embryos arrest at the two-
cell stage and display condensed chromosomes
without separation of sister chromatids. a-tubulin,
red; Anti-centromeric antigen, ACA, green; DAPI,
blue. Scale bars, 10 mM.
(C) Cdc20(lox/lox); RERT2(+/+) females were
crossed with Cdc20(+/); RERT2(Cre/Cre) males,
injected with 4-OHT by E10.5 or E12.5 (Figure S2),
and embryos were extracted 24 hr later. In control
(Cdc20(+/D); RERT2(+/Cre)) samples, most cells
are interphasic or display anaphase figures (insets),
as observed in the proliferating neuroepithelium.
Cdc20-deficient embryos display a dramatic accu-
mulation of cells in metaphase. Some of these
metaphases are positive for BrdU after a 6 hr pulse
with this marker. However, most metaphase cells
are negative for BrdU, indicating that they have
been arrested in metaphase during longer periods.
Cdc20 null cells also display a dramatic accumula-
tion of cyclin B1 after specific immunostaining.
Scale bars, 20 mM (H&E) or 10 mM (immunohisto-
chemistry).
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Tumor Regression by Genetic Ablation of Cdc20Cdk1. This results in the subsequent inhibition of Cdk1 and acti-
vation of separase, a protease that cleaves cohesion complexes
that maintain sister chromatids together (Peters, 2006; Sullivan
and Morgan, 2007). In yeast, inhibition of Cdk1 and separase
activity also results in the activation of Cdc14 phosphatases
that remove mitotic phosphates, thus triggering mitotic exit
(Stegmeier and Amon, 2004; Sullivan and Morgan, 2007). The
overall mechanism is thought to be conserved in vertebrates,
although the relevance of the different molecular pathways
involved is not clear. First, strong RNAi against Cdc20 or the
APC/C catalytic subunit Apc2 has failed to induce mitotic arrest
in some studies (Baumgarten et al., 2009; Gimenez-Abian et al.,
2005), probably as a consequence of residual Cdc20 activity
(Wolthuis et al., 2008). Second, inhibition of Cdk1-cyclin B may
be insufficient for mitotic exit in the presence of proteasome
inhibitors, and a new mechanism involving proteasome-depen-
dent degradation of phosphatase inhibitors has been proposed
(Skoufias et al., 2007). Finally, vertebrate Cdc14 phosphatases
do not seem to play a critical role in mitotic exit (Queralt and Uhl-
mann, 2008), and PP1 or PP2Amay function asmitotic exit phos-
phatases, at least in Xenopus (Mochida et al., 2009; Vigneron
et al., 2009; Wu et al., 2009). In this manuscript we investigate
the requirements for mitotic exit in mammals and their implica-
tion in cancer therapy by using a conditional mutation in the
murine Cdc20 gene.
RESULTS
Genetic Ablation of Cdc20 Results in Metaphase Arrest
In Vivo
The conditional null mutation in the mouse Cdc20 gene was
generated by homologous recombination in ES cells (see Fig-642 Cancer Cell 18, 641–654, December 14, 2010 ª2010 Elsevier Incure S1 available online). Cdc20(+/) mice are viable and fertile.
As previously shown using a gene-trap allele (Li et al., 2007),
lack of Cdc20 results in embryonic lethality at the two-cell stage
(Figures 1A and 1B). These cells arrest in metaphase by E1.5 and
display abnormal mitotic figures during the following days, prob-
ably as a consequence of prolonged metaphase arrest. For
conditional ablation in vivo, we made use of a conditional allele
(Cdc20(lox)) in which exon 2 is flanked by loxP sites (Figure S1).
In these animals a tamoxifen-inducible form of the Cre recombi-
nase (Cre-ERT2) (Guerra et al., 2003) is expressed from the 30-
UTR of the RNA polymerase II gene (RERT allele). Pregnant
females were treated at E10.5 (Figure 1C) or E12.5 (Figure S2)
with 4-hydroxytamoxifen (4-OHT) to induce Cre activity and
excision of exon 2 (Cdc20(D) allele). Cdc20(/D); RERT(+/Cre)
embryos that inherit aCdc20() null allele and aCdc20(lox) allele
display a dramatic arrest in development 24 hr after activation of
the Cre recombinasewith 4-OHT. A detailed histological analysis
of these samples reveals a general proliferative arrest character-
ized by the presence of abundant metaphase figures and high
levels of cyclin B in all proliferating tissues (Figure 1C; Figure S2).
To further investigate whether Cdc20 is also required at post-
embryonic stages, we fed 1 month old Cdc20(/lox); RERT
(+/Cre) mice and control littermates carrying a Cdc20(+) wild-
type allele or lacking Cre with a 4-OHT supplemented diet.
This treatment does not significantly modify the viability of
control mice. However, all Cdc20(/D); RERT(+/Cre) mice die
after 8–10 days on the 4-OHT diet (Figure 2A). This death is likely
to be associated with the dramatic loss of weight in Cdc20(/D);
RERT(+/Cre) mice, but not in the Cdc20(+/D); RERT(+/Cre),
Cdc20(+/lox); RERT(+/+), or Cdc20(/lox); RERT(+/+) control
groups (Figure 2B). Genetic disruption of Cdc20 results in several
histological abnormalities in different tissues. Specifically,.
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Figure 2. Cdc20 Is Essential for Prolifera-
tion in Adult Mice
(A and B) Young mice (P21) were fed with a transi-
tion diet and then supplemented with 4-OHT (A).
This results in rapid lethality in Cdc20(/D);
RERT2(+/Cre) mice that correlates with (B)
a dramatic loss of weight. ***p < 0.0001.
(C) These Cdc20-deficient mice display abundant
metaphase-arrested cells in most proliferating
tissues, including the testis and the intestine.
H&E staining.
(D) Cell proliferation (Ki67) in the intestine of young
Cdc20(/D);RERT(+/Cre) and control Cdc20(+/D);
RERT(+/Cre) mice after conditional induction of
Cre. The ratio of Ki67-positive cells in the epithe-
lium is also plotted. Similar differences are found
in testis and spleen (Figure S2).
(E) Conditional ablation of Cdc20 in 1 year old
mice. These animals were exposed to a transition
diet for 10 days and then supplemented with
4-OHT for 60 days. Control animals (blue) included
Cdc20(+/lox);RERT(+/+) (n = 4), Cdc20(/lox);
RERT(+/+) (n = 4), and Cdc20(+/D);RERT(+/Cre)
(n = 4). Mice with these genotypes displayed
a similar behavior and are grouped in the analysis.
Cdc20 null mice (Cdc20(/D);RERT(+/Cre); n = 8;
green) displayed a significant reduction in weight,
and most of them died within the first month.
However, two of these Cdc20 mutant mice
survived during the assay, similarly to control
mice. Scale bars, 50 or 10 mM (insets).
Data in (B), (D), and (E) are represented as
mean ± SD.
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Tumor Regression by Genetic Ablation of Cdc20proliferative areas in diverse tissues such as intestine and testis
display abundant mitotic figures representative of metaphases,
suggesting that the lack of Cdc20 causes widespread meta-
phase arrest in proliferating cells in vivo (Figures 2C and 2D;
Figure S2). The phenotype induced by Cdc20 loss in intestinal
epithelium suggests that Cdc20(/D); RERT(+/Cre) mice die
because of impaired absorption of nutrients. Genetic ablation
of Cdc20 in older (1 year old) mice results in similar cellular
defects in proliferating cells. However, these treated mice
display improved survival. Two out of eight older mice can
survive for several months despite the absence of Cdc20
expression, suggesting that these mice are less susceptible to
the physiological consequences of loss of proliferation
(Figure 2E).Cancer Cell 18, 641–654, DCdc20 Is Essential for Anaphase
Onset in Progenitor and Tumor
Cells
To determine whether genetic ablation
of Cdc20 is less harmful in quiescent
cells, we analyzed slowly proliferating
progenitor/stem cells. A single topical
treatment with 4-OHT in Cdc20(/lox);
RERT(+/Cre) mice results in a significant
increase in metaphase figures in the
basal layer of the epidermis. However,
no metaphase figures are observed in
the hair follicles, where hair progenitor/stem cells reside (Figure 3A). To induce proliferation of progen-
itor cells and hair regeneration, mice were depilated 8 days after
a single 4-OHT application. Following this treatment, abundant
metaphase figures are observed in multiple cells in the hair folli-
cles, including CD34-positive progenitor cells. This hair regener-
ation response is impaired in Cdc20(/D); RERT(+/Cre) mice
without the need of further 4-OHT applications (Figure 3A).
These data suggest that elimination of Cdc20 in nonproliferating
cells is silent during quiescence or interphase; however, meta-
phase arrest is observed once these cells are committed to
cell division. Similar ablation of Cdc20 in hematopoietic progen-
itor/stem cells also results in metaphase arrest and complete
impairment in the formation of colonies ex vivo (Figures 3B
and 3C).ecember 14, 2010 ª2010 Elsevier Inc. 643
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Figure 3. Cdc20 Is Essential for Mitosis in Progenitor Cells
(A) Eight days after a single topical treatment with 4-OHT, a significant number of proliferating cells in the basal layer of the epidermis (E) are arrested in mitosis
(asterisks) in Cdc20-deficient (Cdc20(/D); RERT2(+/Cre)), but not control (Cdc20(+/D); RERT2(+/Cre)) mice. No metaphase figures are observed in the hair folli-
cles (HF). After depilation of these animals, most hair follicles are abnormal and display abundant cells arrested in mitosis (arrows) without further treatment with
4-OHT. Some of these metaphase cells are positive for CD34, a marker of hair follicle progenitors. This does not represent normal mitotic proliferation because
hair regeneration is significantly impaired in these Cdc20-deficient mice, as observed in the back of these animals 15 days after depilation. H&E staining or
immunodetection of CD34 (insets). Bars indicate 50 or 10 mm (CD34 insets).
(B) Representative micrographs of Cdc20(/D);RERT(+/Cre) spleen and bone marrow before and after treatment with 4-OHT. Metaphase figures are abundant
4 days after treatment with 4-OHT in both organs. H&E staining. Scale bars, 50 or 10 mM (insets).
(C) Colony formation assay of hematopoietic precursors. Equal number of cells from the bone marrow of the indicated genotypes was plated in Methocult plates.
These cells were then cultured in the presence of 4-OHT, and the number of colonies (mean ± SD) was scored after 12 days.
Cancer Cell
Tumor Regression by Genetic Ablation of Cdc20The strong requirement for Cdc20 in normal proliferative cells
prompted us to analyze whether Cdc20 is also essential for
mitosis in tumor cells in vivo. Skin tumors were induced using
the two-stage carcinogenesis protocol in Cdc20(/lox) mice ex-644 Cancer Cell 18, 641–654, December 14, 2010 ª2010 Elsevier Incpressing the inducible Cre recombinase. 4-OHT was topically
applied on the skin when these tumors reached a volume of
50mm3 (about 4 weeks after they were first observed). As shown
in Figures 4A and 4B (and Figure S3), tumors continue to grow.
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Figure 4. Cdc20 Ablation Results in Arrest
of Skin Tumors In Vivo
(A) Skin tumors were induced by the two-stage
carcinogenesis protocol, and papillomas were
topically treated with 4-OHT when they reached
50 mm3 of volume.
(B) Fold increase in tumor volume by week 5
(1 week after treatment with 4-OHT) or week 15
(mean ± SD). See also Figure S3.
(C) Representative pictures of papillomas before
(week 0) or after treatment (week 15).
(D) Micrographs of skin tumor sections (week 15)
of the indicated genotypes showing a few mitotic
figures (anaphase; arrows) in control tumors and
massive mitotic arrest (mostly metaphase; arrow-
heads) and apoptosis (active-caspase 3 (CA3)-
positive cells) in Cdc20-deficient tumors. Scale
bars, 50 or 10 mM (insets).
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Tumor Regression by Genetic Ablation of Cdc20exponentially in Cdc20(+/lox); RERT(+/+) as well as Cdc20(+/D);
RERT(+/Cre) mice. However, these tumors arrest completely in
Cdc20(/D); RERT(+/Cre) mice soon after 4-OHT treatment. In
most cases these tumors acquire a whitish appearance, dry,
and fall off and are no longer observed in the skin of these treated
mice (Figure 4C). Histological observation of treated tumor
samples indicates that lack of Cdc20 results in a massive arrest
of tumor cells in metaphase-like stages. These tumor samples
also contain abundant apoptotic figures (Figure 4D) that are
not frequently observed in normal Cdc20-deficient epithelial
tissues.
Since these skin tumors are relatively benign, we also
analyzed aggressive fibrosarcomas induced by Cdc20(lox/lox);
RERT(+/Cre) fibroblasts expressing H-ras V12 and E1A, two
oncogenes that disrupt major tumor suppressor pathways,
such as the retinoblastoma protein route in human tumors.
Primary mouse embryonic fibroblasts (MEFs) were transfected
with RasV12 and E1A-expressing vectors, and transformed
foci were used to generate stable clones. Application of 1 mMCancer Cell 18, 641–654, D4-OHT in these cultures results in
a dramatic mitotic arrest at 24 hr, and
most cells are either arrested in meta-
phase or apoptotic at 48 hr (Figures 5A–
5D). The application of 4-OHT has no
effect in Cdc20(+/lox); RERT(+/Cre)
control cells (data not shown). When
Cdc20(lox/lox); RERT(+/Cre) or control
transformed cells are injected in SCID-
immunosuppressed mice, rapid and
aggressive fibrosarcomas are observed
within 1–2 weeks. 4-OHT was systemi-
cally applied to these animals when
tumors reached 350 mm3, and tumor
volume was scored afterward. As dis-
played in Figures 5E and 5F, and Fig-
ure S3, the size of all these tumors slightly
increased during the first 1–3 days after
4-OHT treatment. However, Cdc20
(D/D); RERT(+/Cre) tumors stop growing
and dramatically regress until they arealmost undetectable 16 days after treatment. Control tumors,
on the other hand, grow exponentially until mice were sacrificed
for ethical reasons. Histological examination of Cdc20(lox/lox);
RERT(+/Cre) untreated tumors or control (Cdc20(lox/lox);
RERT(+/+) or Cdc20(+/+); RERT(+/Cre)) tumors treated with
4-OHT during 8 days shows frequent mitotic (mostly anaphase)
figures in agreement with the rapid growth of these tumors.
However, Cdc20(D/D); RERT(+/Cre) tumors treated with
4-OHT display massive mitotic arrest and apoptotic cell death
(as measured by active caspase 3) as soon as 4 days after treat-
ment (Figure 5G). We have also tested whether apoptotic cell
death in Cdc20-deficient cells is mediated by p53 by using
Cdc20(lox/lox); p53(/) double-mutant MEFs. In these cells
the apoptotic cell death induced by Cdc20 ablation is not
prevented by p53 deletion (Figure S3). Overall, these results
indicate that Cdc20-directed therapies may be efficient in
most tumor types, regardless of their alteration in Ras, pRb, or
p53 routes, three of the most frequently mutated pathways in
human cancer.ecember 14, 2010 ª2010 Elsevier Inc. 645
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Figure 5. Elimination of Cdc20 Results in Complete Regression of Aggressive Tumors In Vivo
(A)Cdc20(lox/lox); RERT(+/Cre) MEFs were transformed with a combination of Ras + E1A oncogenes, andCdc20 exons were excised adding 1 mM4-OHT. Scale
bars, 50 mM.
(B) Efficient excision of Cdc20 exons generating the Cdc20(D) allele 48 hr after addition of 4-OHT.
(C) Propidium iodide staining showing a dramatic accumulation of 4N Cdc20(D/D); RERT(+/Cre) cells 24 hr after addition of 4-OHT. Most sub-4N cells at 48 hr
correspond to apoptotic cells as determined by Annexin V staining (Figure S4).
(D) Detection of phospho-histone H3 (P-H3) cells by immunofluorescence 0 and 24 hr after addition of 4-OHT. P-M, prophase to metaphase; A-T, anaphase and
telophase.
(E) Ras+E1A transformed MEFs of the indicated genotypes were subcutaneously injected in SCID mice, and tumors were scored every 3 days. These mice were
then injected i.p. (three injections in 1 week) with 4-OHT when the aggressive subcutaneous tumors reached about 350 mm3 of volume (day 12; arrow).
Ten tumors of each genotype treated with 4-OHT or non-treated (NT) were scored. The average tumor volume ± SEM is shown. See Figure S3 for additional data.
(F) Representative images of a fibrosarcoma in a Cdc20(lox/lox); RERT(+/Cre) mouse before (day 10) and 14 days (day 24) after 4-OHT.
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Cancer Cell
Tumor Regression by Genetic Ablation of Cdc20Efficient Mitotic Arrest and Apoptosis in the Absence
of Cdc20
Multiple mitotic drugs are currently used in the clinic to treat
tumors, and new small-molecule inhibitors are under clinical
development. Therefore, we compared the effects of Cdc20
ablation with microtubule stabilizing (taxol) or destabilizing
(vincristine) agents or with two mitotic drugs currently in clinical
trials: BI2536 (a Plk1 inhibitor) and monastrol (an inhibitor of the
kinesin Eg5). Tumoral Cdc20(lox/lox); RERT(+/Cre); H-ras-E1A
cells co-expressing a histone H2B-GFP reporter were treated
with 4-OHT (to disrupt Cdc20) or with the indicated drugs,
and their fate was followed by videomicroscopy during
3 days. Control cells (treated with DMSO) typically undergo
3–4 cell divisions, whereas genetic ablation of Cdc20 results
in metaphase arrest. All Cdc20-deficient cells undergo
apoptosis from this mitotic arrest with an average latency of
20 ± 11 hr, as detected by videomicroscopy and Annexin-V
staining (Figure 6A; Figure S4). Interestingly, this dramatic effect
is not achieved by any of the administrated mitotic drugs.
Whereas a few cells die in mitosis or interphase (red and green
lines in Figure 6A), most cells treated with these chemicals are
alive and undergo several rounds of mitotic entry and exit. In
fact, whereas Cdc20 ablation kills 50% of cells by 18 hr after
mitotic entry, none of the drugs reaches these levels of lethality
during the 72 hr recorded in this assay (Figures 6A and 6B). In
addition, about 50% of cells treated with mitotic drugs incorpo-
rate the nucleotide analog EdU when added 24 hr after the
mitotic inhibitors. This figure is reduced to less than 10% in
Cdc20(lox/lox); RERT(+/Cre) cells after 4-OHT treatment (Fig-
ure S4). This background is probably due to cells in which
4-OHT was not active or in which the remaining amount of
Cdc20 was enough for mitotic exit. In fact all these cells arrest
in metaphase in the following cycle as observed by videomicro-
scopy (data not shown). DNA replication in cells treated with
mitotic drugs results in increased ploidy that is not observed
in Cdc20 null cells (Figure S4).
Given the relevance of mitotic poisons in the clinic, we also
compared the therapeutic effect of Cdc20 ablation versus stan-
dard treatments with taxol, vincristine, or the Plk1 inhibitor
BI2536. Cdc20(lox/lox); RERT(+/Cre); H-ras; E1A cells were in-
jected into SCID mice as described above, and 4-OHT or the
indicated drugs were injected i.p. 11 days after the xenotrans-
plant (tumor size 200 mm3). These treatments were repeated
three times a week. In these conditions, control tumors grow
exponentially, whereas genetic ablation of Cdc20 results in
complete tumor regression in about 10 days. In comparison,
treatment with taxol, vincristine, and BI2536 only induces partial
responses (Figure 6C). In agreement with the data observed
in vitro, immunohistochemical analysis of samples taken
3 days after the first treatment indicates lack of proliferation
(as measured by BrdU incorporation) and massive apoptosis in
Cdc20 null cells, whereas all other samples maintain significant
levels of proliferation and reduced apoptotic markers (Figure 6D;
Figure S4).(G) Histological sections of tumors 4 days after the first injectionwith 4-OHT (day 1
control tumors or before the application of 4-OHT. Cdc20(D/D); RERT(+/Cre) tu
frequent apoptotic figures (lower insets). CA3, immunodetection of active caspa
CanInactivation of Mastl Synergizes with Cdk1 Inhibition in
Mitotic Exit Downstream of Cdc20
To gain further insights into themolecular defects caused by lack
of Cdc20, primary Cdc20(lox/lox) MEFs were transduced with
adenoviruses expressing either the green fluorescent protein
(GFP) or the Cre recombinase. Expression of Cre, but not GFP,
in confluent cells efficiently excises exon 2 resulting in the
Cdc20(D) null allele, and results in the accumulation of mitotic
(MPM2-positive and phospho-H3-positive) cells (Figure S5).
These Cdc20(D/D) cells are arrested in metaphase, whereas
post-metaphase figures (anaphase, telophase, or cytokinesis)
are rarely observed. Lack of Cdc20 results in a significant
increase in cyclin B1 and cyclin A2 protein levels, whereas the
stabilization of securin is not as evident. Mad2 and p21Cip1
protein levels are decreased in Cdc20 null cells, suggesting
that the spindle assembly checkpoint is satisfied and that
p21Cip1 may be targeted by additional proteolytic regulators
(Figure S5).
We next tested whether the elimination of securin and cyclin B
could rescue the metaphase arrest in Cdc20 null cells as previ-
ously demonstrated in yeast (Shirayama et al., 1999; Thornton
and Toczyski, 2003; Wa¨sch and Cross, 2002). Individual knock-
down of securin or cyclin B1 by RNAi did not rescue the mitotic
arrest of Cdc20 null cells (data not shown). Because mammalian
cells also express other B-type cyclins that can compensate for
lack of cyclin B1, we decided to test the effect of chemical
inhibitors of Cdks. Cdc20-depleted cells were treated with
small-molecule inhibitors of Cdks (roscovitine, purvalanol A,
RO-3306, and GCP-74514A) or other kinases such as Plk1
(GW843682X) or Aurora B (ZM447439) as additional controls.
In addition a general kinase inhibitor (staurosporine) with prefer-
ence to AGC (PKC family) kinases was also used. Mitotic exit
(as determined by loss of rounded,morphology, decondensation
of chromosomes, and loss of phospho-MPM2, phospho-H3,
and Cdk-dependent phosphosites) is induced by the Cdk inhib-
itors RO-3306 and GCP-74514A whereas two other Cdk inhibi-
tors (roscovitine and purvalanol A) are not efficient in inducing
mitotic exit in this assay (Figure S5). These differences have
been previously observed in human cells treated with protea-
some inhibitors (Potapova et al., 2006; Skoufias et al., 2007),
and they are likely to be due to differences in specificity and
potency of these drugs.
To further study the components of the mitotic exit machinery
in Cdc20 null cells, we decided to use roscovitine for three
reasons. First, it is a very specific inhibitor of Cdks (Bain et al.,
2007). Second, it significantly inhibits Cdk1 kinase activity,
even in Cdc20 null cells that display strong Cdk1 activity (Fig-
ure S5). Finally, it rapidly induces mitotic exit in nocodazole-
arrested cells (Figures 7A and 7B), in agreement with the require-
ments for Cdk1 activity to sustain the spindle assembly
checkpoint in these conditions (D’Angiolella et al., 2003).
In Cdc20 null cells, neither roscovitine alone nor the combina-
tion of roscovitine and securin RNAi allows sister chromatid
separation or mitotic exit, and these cells remain in metaphase6). Upper insets represent anaphase figures surrounded by interphase figures in
mors massively arrest in metaphase 4 days after treatment and accumulate
se 3. Scale bars, 50 or 10 mM (insets).
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Figure 6. A Comparison between Genetic Ablation of Cdc20 and Current Mitotic Drugs
(A) Cdc20(lox/lox); RERT(+/Cre); H2B-GFP cells transformed with H-ras and E1A oncogenes were treated with 4-OHT to generate Cdc20(D/D) cells or with the
indicated mitotic inhibitors. Twenty-four hours after the treatment, cells were recorded by videomicroscopy during an additional 72 hr, and their transition trough
mitosis or interphase is shown by colored lines. Red or green lines indicate mitosis or interphase ending in apoptosis. Blue and gray lines indicate normal alter-
nation between mitosis and interphase. Every raw indicates the fate of individual cells (n = 44 per treatment).
(B) Ratio of live cells and duration of mitosis in Cdc20 null cells (red) and control Cdc20(lox/lox) cells treated with vincristine (blue), monastrol (green), taxol
(orange), and the Plk1 inhibitor BI2536 (gray). All Cdc20 null cells die within 48 hr without being able to exit mitosis, whereas more than half of the cells treated
with mitotic drugs exit mitosis and are viable during the first 72 hr.
(C) Transformed Cdc20(lox/lox); RERT(+/Cre) MEFs were subcutaneously injected into the two flanks of SCID mice, and tumors were scored every 2–3 days.
These mice were injected i.p. (three injections per week) with 4-OHT or mitotic drugs (taxol, vincristine, and BI2536) when tumors reached about 200 mm3 of
volume (day 11; arrow) (n = 8 mice per group).
(D) Representative images of these fibrosarcomas 3 days after injection with 4-OHT (to generate Cdc20(D/D) cells), BI2536, or taxol. These mice were injected
with 10 mM BrdU to score DNA replication. CA3, immunodetection of active caspase 3. Scale bars, 50 or 10 mM (insets). Additional data are shown in Figure S4.
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Figure 7. Cdc20-Dependent Mitotic Exit Can Be Triggered by Concomitant Inhibition of Cdk and Mastl Kinases
(A)Cdc20(lox/lox) cells were infectedwith AdCre (Cdc20(D/D)) or treatedwith nocodazole (Noc), siRNAs against securin (siSec), roscovitine (Ros), or okadaic acid
(OA). None of these treatments inducedmitotic exit (asmeasured by dephosphorylation of Cdk substrates) in Cdc20-deficient cells, although Ros induced anOA-
inhibitable mitotic exit in nocodazole-arrested cells (see also Figure S5).
(B) The percentage ofmitotic cells (mean ± SD as scored by DAPI staining) in the different conditions is indicated in the histograms showing strong correlation with
the Cdk-dependent phospho-Ser mark.
(C) Representative metaphase-arrested cells in the previous assay. The ratio of metaphase cells is indicated (normalized to Cdc20(D/D)). Phospho-histone H3,
yellow; a-tubulin, red; DAPI, blue. Metaphase spreads are shown in the right panels indicating cohesion between sister chromatids in these cells.
(D) Double-mutant Cdc20(D/D); Pttg1(D/D) cells were transfected with siRNAs against Mastl (siMastl) or scrambled siRNAs (siCtrl). These cells were also treated
with roscovitine (Ros) or OA as indicated and analyzed 48 hr postinfection with AdCre (0 hr) or after 3 hr in the presence of Ros and/or OA. Mitotic exit is only
observed after concomitant inhibition of Cdk1 and elimination of Mastl. The indicated proteins or phospho-epitopes were analyzed by immunoblotting, and
the relative levels of phospho-Cdk-substrates are normalized versus siCtrl at t = 0.
(E) Representative micrographs of cells or metaphase spreads in these cultures. The ratio of cells in metaphase or with decondensed chromosomes is indicated
(normalized to cells treatedwith scramble siRNAs). An additional culture (right panels) shows the effect of a humanGFP-tagged-Mastl cDNA insensitive to siRNAs
(hMastl; green signal). P-H3, yellow; a-tubulin, red; DAPI, blue. Scale bars indicate 10 mM in immunofluorescence images and 2 mM in metaphase spreads.
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Tumor Regression by Genetic Ablation of Cdc20without separation of sister chromatids (Figures 7A–7C; Fig-
ure S5). We also combined Cdc20 mutant alleles with Pttg1
(encoding securin) conditional alleles (Wirth et al., 2006), thus
eliminating any residual securin after RNAi assays. Cdc20(D/D);
Pttg1(D/D) double-mutant MEFs arrest in metaphase similarly to
Cdc20(D/D); Pttg1(+/+) cells, and the addition of roscovitine has
only a minor effect on mitotic exit (Figure 7D; Figure S5). Rosco-
vitine-treated Cdc20; securin null cells are arrested in meta-
phase with high levels of phosphorylation of Cdk substrates
(Figures 7D and 7E), suggesting that mitotic phosphatases
cannot be activated in the absence of Cdc20. The fact that
500 nM of okadaic acid (OA), a concentration known to preferen-
tially inhibit PP2A (Felix et al., 1990; Wu et al., 2009), prevents
mitotic exit by roscovitine in nocodazole-arrested cells (Figures
7A and 7B) (Skoufias et al., 2007), suggests that PP2A may
participate in mammalian mitotic exit as previously suggested
in Xenopus (Mochida et al., 2009).
Recent data obtained in Xenopus suggest that PP2A may be
inactivated by theGreatwall kinase (known asMastl inmammals,
a kinase that belongs to the AGC family represented by PKC, the
original target of staurosporine), thus supporting the mainte-
nance of Cdk-dependent phosphosites and the mitotic state
(Castilho et al., 2009; Vigneron et al., 2009). Therefore, we tested
whether the elimination of Mastl could cooperate inmitotic exit in
Cdc20-deficient cells. Knockdown of Mastl by RNAi (siMastl) in
Cdc20(D/D); Pttg1(D/D) double-mutant MEFs induces partial
defects inmitotic entry (data not shown), consistent with a recent
report in human cells (Burgess et al., 2010). However, most
Cdc20 null cells eventually arrest in metaphase with high levels
of phospho-Cdk substrates and without sister chromatid sepa-
ration. Interestingly, Cdc20(D/D); Pttg1(D/D); Mastl RNAi cells
quickly exit frommitosis after treatment with roscovitine. In these
cells, Cdk substrates are dephosphorylated, and DNA decon-
denses generating tetraploid cells, in some cases containing
micronuclei, most likely as a consequence of rapid decondensa-
tion without separation of sister chromatids (Figures 7D and 7E).
Although this mitotic exit is abnormal because it is not accompa-
nied by sister chromatid separation, we have utilized the term
‘‘mitotic exit’’ throughout the manuscript to indicate loss of
mitotic properties (loss of rounded morphology, chromosome
decondensation, loss of mitotic phospho-residues). The effect
of RNAi against Mastl is specific because it can be rescued by
transfecting Cdc20 null cells with a human Mastl cDNA insensi-
tive to the RNAi oligonucleotides (Figure 7E). Thus, interference
of Mastl expression synergizes with roscovitine in mitotic exit
in Cdc20;securin-deficient cells. This cooperation is also
observed in Cdc20 null cells in the presence of securin (data
not shown), and it affects dephosphorylation of Cdk substrates,
but not sister chromatid separation.
Mitotic Exit Requires Activation of PP2A/B55
Complexes
The combined effect of Mastl RNAi and roscovitine is sup-
pressed by 500 nM OA, thus suggesting that PP2A acts down-
stream of Mastl during mammalian mitotic exit (Figure 7D).
It has been recently proposed that B55d is the regulatory
subunit of PP2A in mitotic exit in Xenopus (Mochida et al.,
2009). Indeed, whereas downregulation of all mammalian B55
genes (B55a,b,g,d) has no major effect on metaphase-arrested650 Cancer Cell 18, 641–654, December 14, 2010 ª2010 Elsevier Inccells (Figure S6), it dramatically suppresses mitotic exit after
combined inactivation of Cdk1 andMastl (Figure 8A), suggesting
that B55 proteins are the major regulatory subunits of PP2A
during mitotic exit. The B55a (Ppp2r2a) and B55d (Ppp2r2d)
isoforms are widely expressed in mammalian cells (including
fibroblasts), whereas B55b (Ppp2r2b) and B55g (Ppp2r2c) are
restricted to the nervous system (Eichhorn et al., 2009). In fact,
downregulation of B55b does not prevent mitotic exit mediated
by Cdk1 inhibition and Mastl suppression in Cdc20 null cells.
However, suppression of B55a prevents 60% of mitotic exit (as
determined by phosphorylation of Cdk substrates), whereas
B55d accounts for 40% of the phospho-Cdk-substrate signal
(Figure 8B), indicating that both B55a and B55d participate in
the PP2A functional complexes required for mitotic exit in
Cdc20 null fibroblasts. RNAi against B55 is also able to prevent
mitotic exit in human or murine cells arrested with proteasome
inhibitors (Figure S6). HeLa or B16F10 melanoma cells arrested
in metaphase by MG132 do not exit frommitosis upon treatment
with roscovitine, similar to other human cells (Potapova et al.,
2006; Skoufias et al., 2007). However, concomitant treatment
with roscovitine and Mastl RNAi results in rapid PP2A-B55-
dependent mitotic exit (Figure S6).
Both PP1 and PP2A may participate in mitotic exit in Xenopus
(Mochida et al., 2009; Wu et al., 2009). In this model, dephos-
phorylation of PP1 inhibitor-1 (Inh1) leads to its dissociation
from the catalytic subunit and full PP1 activation (Wu et al.,
2009). Therefore, we tested the effect of suppression of Inh1 in
Cdc20 null cells. As shown in Figure S6, suppression of mouse
Inh1 (Ppp1r1a) by RNAi results in a partial dephosphorylation
of Cdk substrates in the presence of roscovitine. Interestingly,
this exit is sensitive to 500 nM OA, suggesting that PP2A acts
downstream of PP1 in mitotic exit. Thus, both phosphatases
are likely to play a role in mammalian mitotic exit downstream
of Cdc20, although their relative roles are yet to be established.
Altogether, these data suggest that the concomitant inhibition
of Cdk1 and Mastl is a general mechanism for PP2A-mediated
mitotic exit downstream of Cdc20 in both mouse and human
cells. Whereas all Cdc20 null cells die in mitosis (Figure 6),
a number of interphasic Cdc20 null cells in which Cdk1 andMastl
have been inhibited display increased viability and are able to
enter into DNA replication (Figure S6). Thus, the inhibition of
these mitotic kinases could counteract the therapeutic effect
of inhibiting APC/C-Cdc20 in tumor cells.DISCUSSION
Conditional genetic elimination of Cdc20 results in complete
metaphase arrest in embryonic or somatic cells in vivo. Mitotic
exit is likely to be efficient with as little as 5% of cellular Cdc20
(Wolthuis et al., 2008), giving an explanation for previous reports
indicating that Cdc20 knockdown by RNAi does not result in
cyclin B stabilization or mitotic arrest (Clarke, 2009). Cdh1 is
not able to compensate for the lack of Cdc20. This is not due
to differences in substrate specificity because Cdh1 is also
able to target securin and cyclin B for degradation. Rather, this
reflects the fact that Cdc20 absence arrests cells with high
Cdk1 activity, and this activity is known to inhibit Cdh1 function
(Manchado et al., 2010)..
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Figure 8. Mitotic Exit Is Inhibited by the
Mastl Kinase and Requires PP2A-B55a,d
Complexes
(A) Double-mutant Cdc20(D/D); Pttg1(D/D) cells
were transfected with specific siRNAs against
Mastl (siMastl) and a pool of siRNAs against all
B55 isoforms (siB55pool) showing that depletion
of B55 prevents mitotic exit induced by siMastl +
roscovitine (Ros), similar to treatment with okadaic
acid (OA). The indicated proteins or phospho-
epitopes are analyzed by immunoblotting, and
the relative levels of phospho-Cdk-substrates are
normalized versus control cultures without drugs.
See Figure S6 for similar assays in human cells.
(B) Relative rescue of mitotic exit (as measured by
the phospho-Cdk-substrate epitope) by specific
siRNAs against B55a, B55b, and B55d in Cdc20-
deficient cells treated with roscovitine (Ros) and/
or OA and siRNAs against Mastl (siMastl). The
relative levels of phospho-Cdk-substrates or the
indicated proteins are shown after immunoblot.
Cdk-dependent phospho-residues are also quan-
tified and normalized independently (relative to the
respective control cells in the absence of Ros or
OA that are arbitrarily set to ‘‘1’’) to eliminate rela-
tive differences in the loading of proteins.
(C) A model for mitotic exit induced by Cdc20 in
mammals. The relevance of Pttg1/securin degra-
dation by Cdc20 (dashed line) is not clear because
it is dispensable in the presence of cyclin B, and
Pttg1 levels are not significantly increased in
Cdc20 null cells. Mastl is a critical node in the
pathway to inactivate PP2A/B55a,d complexes.
The presence of cyclin B may inhibit mitotic exit,
even upon chemical inhibition of Cdk1, e.g., by
physical interaction with separase (Gorr et al.,
2005) and perhaps Mastl (question mark).
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Tumor Regression by Genetic Ablation of Cdc20Elimination of Cdc20 also has dramatic consequences for
proliferation of tumor cells, in agreement with the recent
proposal that targeting mitotic exit is a better cancer therapeutic
strategy than targeting other cell cycle processes (Huang et al.,
2009). Inhibiting mitotic exit is likely to also affect pRb null, p53
null, or SAC-deficient cells (Huang et al. [2009],and this work).
The toxicity of Cdc20 ablation in proliferative cells is much
stronger than any other treatment with available mitotic drugs,
such as microtubule poisons (taxol or vincristine) or targeted
inhibitors against Plk1 (BI2536) or the kinesin Eg5 (monastrol).
Thus, the essential requirements for Cdc20 during mitosis
suggest possible benefits of inhibiting APC/C function, e.g., byCancer Cell 18, 641–654, Dgenerating small molecules that prevent
the APC/C-Cdc20 interaction. An inter-
esting question that arises from these
observations is whether Cdc20 null cells
(or tumors cells treated with APC/C inhib-
itors) may adapt to this situation (exiting
from mitosis without dying) and what the
molecular requirements are for this exit.
We show here that Cdk1 and Mastl are
required for Cdc20-dependent meta-
phase arrest and apoptosis. Inhibition of
Cdk1 and Mastl strongly synergizes inmitotic exit in the absence ofCdc20bygenerating tetraploid cells.
Whether inhibition of Cdk1 alone by different small-molecule
inhibitors is sufficient for mitotic exit in the presence of
proteasome inhibitors is currently controversial, given the differ-
ences observed with different inhibitors (Potapova et al., 2009;
Skoufias et al., 2007). At the concentrations used in this work,
roscovitine is highly inefficient in inducing mitotic exit in the
absence of Cdc20, although it induces a rapid exit from
nocodazole arrest. Similarly, knockdown of Mastl alone is not
sufficient for mitotic exit in Cdc20 null cells. However,
inhibition of both kinases strongly synergizes and results in
a dramatic removal of Cdk-dependent phosphates and rapidecember 14, 2010 ª2010 Elsevier Inc. 651
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Tumor Regression by Genetic Ablation of Cdc20PP2A-B55a,d-dependent mitotic exit. These data suggest that
partial Cdk1 inhibition is likely to be insufficient to drive mitotic
exit because Cdk1 substrates are already phosphorylated, and
theycannotbedephosphorylatedas longasMastl remainsactive.
Activation of Cdc20 should lead to the inactivation of both
Cdk1 and Mastl, resulting in PP2A activation (Figure 8C). How
Mastl is inactivated downstream of Cdc20 is not clear at this
moment. Mastl contains a consensus KEN box and several
putative D-box domains, although we have not been able to
demonstrate APC/C-mediated degradation of this kinase (Fig-
ure S6). One possibility is that in Cdc20 null cells direct interac-
tion between cyclin B1 and Mastl (Figure 8C) prevents the
efficient inactivation of this protein, even upon chemical inhibi-
tion of Cdk1. This is not a novel mechanism because direct
interaction between cyclin B1 and separase inhibits this
protease, even if Cdk1-dependent phospho-residues have
been eliminated (Boos et al., 2008; Gorr et al., 2005). We have
also observed co-immunoprecipitation of Mastl and cyclin B1
in the same protein complexes (data not shown). Because Mastl
has been proposed to be modulated by Cdk1-dependent phos-
phorylation (Yu et al., 2006), it is difficult to discriminate whether
this represents normal phosphorylation of Mastl by cyclin
B1-Cdk1 complexes or a phosphorylation-independent interac-
tion. The fact that roscovitine is insufficient for dephosphoryla-
tion of Cdk substrates, and this is rescued by Mastl knockdown,
suggests that Mastl or the putative Mastl substrates need to be
dephosphorylated prior to the activation of PP2A. Suppression
of the PP1 inhibitor Inh1 results in a partial exit from mitosis in
the presence of roscovitine, thus suggesting that PP1 could
also participate in this pathway as previously proposed in Xeno-
pus (Wu et al., 2009) (Figure 8C). For instance, PP1 may be
responsible for the elimination of activating phosphates onMastl
or the removal of Mastl-dependent phosphates in its substrates
(Castilho et al., 2009). In agreement with this proposal, PP1 is
likely to act upstream of PP2A because the effect of Inh1
suppression is sensitive to OA. Further focused work will be
necessary to compare the relative roles of these two phospha-
tases duringmitotic exit inmammals. In Cdc20 null cells the elim-
ination of Mastl is necessary to activate PP2A, and full mitotic
exit requires both PP2A/B55a and PP2A/B55d complexes.
Because B55b and B55g are not expressed in primary MEFs,
these results are likely to represent the relative amount of each
of these isoforms in a particular cell type.
Altogether, these results indicate that Cdc20 is an essential
driver of mitotic exit in mammalian normal or tumor cells and
that mitotic exit requires Mastl inhibition and the activation of
PP2A-B55a,d phosphatases. Upon elimination of Cdc20, tumor
cells rapidly die of apoptosis in vitro and in vivo unless Cdk1 and
Mastl kinases are inhibited. This molecular pathway may have
relevant implications for designing future therapeutic strategies
aimed at inhibiting APC/C and for preventing adaptation to the
apoptotic cell death imposed by defective mitotic exit. How to
use these strategies and how to discriminate between normal
and tumor cells have been recently reviewed (Gascoigne and
Taylor, 2009; Rieder andMedema, 2009). For instance, chemical
APC/C-Cdc20 inhibitors could be used as a combinatory
therapy with other mitotic poisons. Partial Cdc20 inhibition
may delay mitotic exit, preventing slippage of tumoral cells,
which is one of the most important mechanisms of resistance652 Cancer Cell 18, 641–654, December 14, 2010 ª2010 Elsevier Incin tumor treated with mitotic drugs. Other strategies to consider
may be the protection of normal cells by impeding their entry into
the cell cycle. For instance, prolonged fasting concomitant to the
delivery of chemotherapy dramatically reduces the toxic side
effects of the treatment, while maintaining its efficacy against
cancer (Raffaghello et al., 2008). Other studies suggest the use
of G1 inhibitors (e.g., Cdk4/2 inhibitors) to arrest normal cells
(pRb proficient) in G0/G1, thus protecting them from toxic
chemotherapies. pRb null tumor cells that do not respond to
these chemicals would enter into the cell cycle, thereby making
them sensitive to chemotoxic treatments (Blagosklonny and
Pardee, 2001). Thus, on one hand, partial Cdc20 inhibition may
synergize with microtubule poisons, but combination with
Cdk1 inhibitors should be avoided. On the other hand, strong
inhibition of APC/C-Cdc20 is likely to be highly efficient in
inducing apoptotic cell death, and this property should be
used in therapeutic scenarios in which proliferation of normal
cells is abrogated, such as after food starvation or in combina-
tion with G1-arresting agents, to selectively protect these normal
cells against efficient mitotic chemotherapies.EXPERIMENTAL PROCEDURES
Generation and Characterization of Cdc20 Mutant Mice
The Cdc20 exon 2 was flanked with loxP sites as indicated in Figure S1. The
conditions for genotyping Cdc20 mutant are available from the authors upon
request. Securin conditional mutants and RERT2 mice were genotyped as
described (Guerra et al., 2003; Wirth et al., 2006). Mouse depilation (Ruzankina
et al., 2007) and induction of skin tumors (Sotillo et al., 2001b) were performed
as reported previously. Mutant mice were fed with 4-OHT-supplemented food
(Harlan Laboratories Models), injected (i.p.) as described by Perera et al.
(2007), or topically painted with 50 ml 4-OHT (5 mg/ml). All animals were main-
tained in a mixed 129/Sv (25%)3 CD1 (25%)3 C57BL/6J (50%) background.
Xenographs were generated using transformed MEFs using SCID mice
(Charles Rivers) essentially as described previously (Sotillo et al., 2001a).
These mice were treated with taxol (Paclitaxel, Sigma; 12 mg/kg), vincristine
(Sigma; 12 mg/kg), and BI2536 (Selleck Chemicals; 35 mg/kg) following the
recommended doses reported previously (Koyanagi et al., 1994; Patel et al.,
2010; Steegmaier et al., 2007). All animal protocols were approved by the
ISCIII committee for animal care and research. For histological observation,
dissected organs were fixed in 10% buffered formalin (Sigma) and embedded
in paraffin wax. Sections of 3 or 5 mm thickness were stained with hematoxylin
and eosin (H&E). Immunohistochemistry was performed using specific anti-
bodies against the following antigens: BrdU (GE Healthcare), Ki67 (Dako),
active caspase 3 (Cell Signaling Technology), cyclin B1 (Chemical Interna-
tional), Cdc20 (Santa Cruz Biotechnology), and CD34 (Abcam).
Cell Culture and Treatments
MEFs were isolated from E13.5 embryos and cultured essentially as described
previously (Garcia-Higuera et al., 2008). Adenoviruses expressing GFP or Cre
(supplied by the Iowa University) and siRNAs against specific transcripts
(Dharmacon) were used following the manufacturer’s recommendations.
Briefly, adenoviruses were transduced in confluency, and cells were split
48 hr after and transfected with siRNAs when required. The following drugs
were used in cultured cells at the indicated concentrations: nocodazole
(Sigma; 100 ng/ml); roscovitine (Sigma; 1–200 mM; see figure legends);
purvalanol A (Calbiochem; 10–100 mM); RO-3306 (Calbiochem; 10–100 mM);
GCP-74514A (Calbiochem; 10–100 mM); Staurosporine (Sigma; 0.1, 1, and
10 mM); Plk1 inhibitors GW843682X (Tocris; 10–100 mM) and BI2536 (Selleck
Chemicals; 100 nM); Aurora B inhibitor ZM447439 (Tocris; 10–100 mM); taxol
(Sigma; 200 nM); and vincristine (Sigma; 1 mM) and monastrol (Sigma;
100 mM). The concentration of taxol, vincristine, BI2536, and monastrol was
selected after testing theminimum saturating concentration required to induce
mitotic arrest inMEFs. MEFswere transformedwith H-ras and E1A oncogenes.
Cancer Cell
Tumor Regression by Genetic Ablation of Cdc20essentially as reported previously (Quereda et al., 2007), and xenographs were
generated by subcutaneous injection of 53 105 cells in SCID mice. For video-
microscopy, H2B-GFP expressing cells were recorded using a Deltavision
Apparatus (Applied Precision) using 10 min frames during 72 hr.
Metaphase Spreads
Cells were hypotonically swollen in 40% full medium/60% tap water for
5.5 min. Hipotonic treatment is stopped by adding an equal volume of
Carnoy’s solution (75% pure methanol, 25% glacial acetic acid), cells are
then spun down and resuspended and fixed with Carnoy’s solution for
10 min. After fixation cells are dropped from a 5 cm height onto glass slides.
Slides are stained with 5% Giemsa in PBS for 7 min.
Immunofluorescence and Biochemical Analysis
Embryos were fixed with cold methanol during 1 hr at 20C, rinsed with M2
medium, washed in PBS containing 0.1% BSA (Sigma), and incubated with
0.1% Triton X for permeabilization. Embryos were then blocked with 3%
BSA and incubated with primary antibodies (see below) for 2–4 hr at 37C.
The matching secondary antibodies (Alexa 488, 594, or 647) are from Molec-
ular Probes (Invitrogen). Images were obtained using a confocal ultra-spectral
microscope (Leica TCS-SP5-AOBS-UV). Cultured cells were grown in cover-
slips, fixed with 4% paraformaldehyde in PBS for 7 min at 37C, permeabilized
with PBS-Triton 0.15% for 2 min at 37C, and blocked with 1% BSA for 1 hr.
Immunofluorescence in embryos or cultured cells was performed using
specific antibodies against the following proteins: phospho-histone H3 (Milli-
pore), a-tubulin (Sigma), and ACA (Antibodies Incorporated). ForWestern blot-
ting, cells were harvested and lysed in RIPA buffer, and 50 mg of total protein
was separated by SDS-PAGE and probed with antibodies against securin
(Abcam), Cdc20 (Santa Cruz), phosphoSer-CDKs substrates (Cell Signaling
Technology), cyclin B1 (Chemicon International), MASTL (Abcam), Inhibitor
1 (Ppp1r1a) (Abcam), B55 (Santa Cruz), alpha-tubulin (Sigma), phospho-
Histone 3 (Millipore), cyclin A2 (Santa Cruz), Mad2 (MBL), p21Cip1 (Santa
Cruz), and a-Actin and a-tubulin (Sigma).
Statistical Analysis
Statistical analysis was performed using Student’s t, chi-square, or log-rank
tests (GraphPad Prism 5). All data are shown as mean ± SD; probabilities of
p < 0.05 were considered significant.
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